Technical Analysis for ALLR - Allarity Therapeutics, Inc.

Grade Last Price % Change Price Change
F 0.30 -3.80% -0.01
ALLR closed down 3.8 percent on Thursday, March 28, 2024, on 2.84 times normal volume. The bears made the stock sink to a new 52-week low. Due to the stock's strong downtrend, it may remain oversold for a while. So, if you're looking for a reason to buy, don't put too much weight on it being oversold.
1 Watcher
Watchlist Portfolio

Trend Table & Recent EOD Trading Signals

ADX Long Term Intermediate Term Short Term
Strong Down Down Down

Date Alert Name Type % Chg
New 52 Week Closing Low Bearish 0.00%
New 52 Week Low Weakness 0.00%
Wide Bands Range Expansion 0.00%
Oversold Stochastic Weakness 0.00%
Inside Day Range Contraction -3.80%
Wide Bands Range Expansion -3.80%
Oversold Stochastic Weakness -3.80%
Pocket Pivot Bullish Swing Setup -2.56%
Lower Bollinger Band Walk Weakness -2.56%
New 52 Week Low Weakness -2.56%

   Recent Intraday Alerts

Alert Time
Possible Pocket Pivot about 3 hours ago
Lower Bollinger Band Support about 6 hours ago
60 Minute Opening Range Breakdown about 7 hours ago
Fell Below Lower Bollinger Band about 7 hours ago
2x Volume Pace about 9 hours ago

Get a Trading Assistant

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.

Profile

Allarity Therapeutics, Inc. Description

Allarity Therapeutics A/S develops various therapeutic candidates for the treatment of cancer using drug-specific companion diagnostics (cDx) generated by its drug response predictor technology. Its lead therapeutic candidate is dovitinib, a second-generation pan-tyrosine kinase inhibitor with the ability to inhibit numerous classes of tumor-driving tyrosine kinases, including FGFR, VEGFR, PDGFR, c-Kit, Flt-3, and CSF-1. The company's therapeutic candidates also include stenoparib, selective inhibitor of the key DNA damage repair enzyme poly-ADP-ribose polymerase; and IXEMPRA, a selective microtubule inhibitor that interferes with cancer cell division through mitotic arrest. It also developing other therapeutic candidates comprising LiPlaCis, a targeted liposomal formulation of Cisplatin; 2X-111, a targeted liposomal formulation of Doxorubicin; and Irofulven, a DNA damaging agent. The company was founded in 2004 and is headquartered in Horsholm, Denmark.


Classification

Sector: Healthcare
Industry: Biotechnology
Keywords: Cancer Health Sciences Drugs Treatment Of Cancer Enzymes Protein Kinase Inhibitor Tyrosine Kinase Doxorubicin Liposome

Is ALLR a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength

Indicators

Indicator Value
52 Week High 154.4
52 Week Low 0.29
Average Volume 123,024
200-Day Moving Average 1.46
50-Day Moving Average 0.40
20-Day Moving Average 0.36
10-Day Moving Average 0.33
Average True Range 0.03
RSI (14) 28.06
ADX 36.43
+DI 6.08
-DI 27.52
Chandelier Exit (Long, 3 ATRs) 0.35
Chandelier Exit (Short, 3 ATRs) 0.38
Upper Bollinger Bands 0.44
Lower Bollinger Band 0.29
Percent B (%b) 0.09
BandWidth 42.20
MACD Line -0.03
MACD Signal Line -0.02
MACD Histogram -0.0047
Fundamentals Value
Market Cap 1.77 Million
Num Shares 5.89 Million
EPS 2625.43
Price-to-Earnings (P/E) Ratio 0.00
Price-to-Sales 0.00
Price-to-Book 2.35
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 0.35
Resistance 3 (R3) 0.35 0.33 0.34
Resistance 2 (R2) 0.33 0.32 0.33 0.34
Resistance 1 (R1) 0.32 0.32 0.31 0.32 0.33
Pivot Point 0.30 0.30 0.30 0.30 0.30
Support 1 (S1) 0.29 0.29 0.28 0.29 0.27
Support 2 (S2) 0.27 0.29 0.27 0.27
Support 3 (S3) 0.26 0.27 0.26
Support 4 (S4) 0.26